多发性硬化首次脱髓鞘事件后不依赖复发活动的早期进展与长期残疾的关联
这项在西班牙一个研究中心开展的队列研究纳入1128例首次脱髓鞘发作的多发性硬化患者,随访至2021年7月31日。277例(25%)出现不依赖复发活动的进展(PIRA),首次发作年龄较大是唯一预测因素(每增加10岁 HR 1.43)。PIRA患者扩展残疾状态量表(EDSS)年增加率更高(0.18 vs 0.04),达到EDSS 6.0的风险是对照的7.93倍;早期PIRA较晚期PIRA预后更差。
要点
- 首次脱髓鞘事件后25%的患者出现不依赖复发活动的进展(PIRA),中位随访7.2年。
- 首次发作年龄较大是PIRA唯一预测因素(每增加10岁 HR 1.43,95%CI 1.23-1.65,P<.001)。
- 早期PIRA较晚期PIRA的EDSS年增加率更高(0.31 vs 0.13),达到EDSS 6.0的风险为26.21倍。
核心结论
- 首次脱髓鞘事件后出现PIRA并不少见,提示长期预后不良,尤其当PIRA发生在疾病早期时。
研究设计与样本
- 这项队列研究于1994年1月1日至2021年7月31日在西班牙1个研究中心开展,纳入1128例首次脱髓鞘发作的多发性硬化患者,平均(SD)年龄32.1(8.3)岁,女性781例(69.2%)。
主要发现
- 277例(25%)出现至少1次PIRA事件,首次PIRA的中位(IQR)随访时间为7.2(4.6-12.4)年。
- 277例PIRA患者中86例(31%)为早期PIRA;144例中有73例(51%)为活动性PIRA。
- PIRA患者较无PIRA者年龄略大、脑病灶更多、寡克隆带阳性更常见。
- PIRA患者EDSS年增加率更陡(0.18;95%CI 0.16-0.20 vs 0.04;95%CI 0.02-0.05;P<.001),达到EDSS 6.0的风险为无PIRA者的7.93倍(HR 7.93;95%CI 2.25-27.96;P=.001)。
- 早期PIRA较晚期PIRA的EDSS年增加率更陡(0.31;95%CI 0.26-0.35 vs 0.13;95%CI 0.10-0.16;P<.001),自首次发作起达到EDSS 6.0的风险为26.21倍(HR 26.21;95%CI 2.26-303.95;P=.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS). OBJECTIVE: To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors associated with long-term clinical outcomes of people who present with PIRA. DESIGN, SETTING, AND PARTICIPANTS: This cohort study, conducted from January 1, 1994, to July 31, 2021, included patients with a first demyelinating attack from multiple sclerosis; patients were recruited from 1 study center in Spain. Patients were excluded if they refused to participate, had alternative diagnoses, did not meet protocol requirements, had inconsistent demographic information, or had less than 3 clinical assessments. EXPOSURES: Exposures included (1) clinical and neuroimaging features at the first demyelinating attack and (2) presenting PIRA, ie, confirmed disability accumulation (CDA) in a free-relapse period at any time after symptom onset, within (vs after) the first 5 years of the disease (ie, early/late PIRA), and in the presence (vs absence) of new T2 lesions in the previous 2 years (ie, active/nonactive PIRA). MAIN OUTCOMES AND MEASURES: Expanded Disability Status Scale (EDSS) yearly increase rates since the first attack and adjusted hazard ratios (HRs) for predictors of time to PIRA and time to EDSS 6.0. RESULTS: Of the 1128 patients (mean [SD] age, 32.1 [8.3] years; 781 female individuals [69.2%]) included in the study, 277 (25%) developed 1 or more PIRA events at a median (IQR) follow-up time of 7.2 (4.6-12.4) years (for first PIRA). Of all patients with PIRA, 86 of 277 (31%) developed early PIRA, and 73 of 144 (51%) developed active PIRA. Patients with PIRA were slightly older, had more brain lesions, and were more likely to have oligoclonal bands than those without PIRA. Older age at the first attack was the only predictor of PIRA (HR, 1.43; 95% CI, 1.23-1.65; P < .001 for each older decade). Patients with PIRA had steeper EDSS yearly increase rates (0.18; 95% CI, 0.16-0.20 vs 0.04; 95% CI, 0.02-0.05; P < .001) and an 8-fold greater risk of reaching EDSS 6.0 (HR, 7.93; 95% CI, 2.25-27.96; P = .001) than those without PIRA. Early PIRA had steeper EDSS yearly increase rates than late PIRA (0.31; 95% CI, 0.26-0.35 vs 0.13; 95% CI, 0.10-0.16; P < .001) and a 26-fold greater risk of reaching EDSS 6.0 from the first attack (HR, 26.21; 95% CI, 2.26-303.95; P = .009). CONCLUSIONS AND RELEVANCE: Results of this cohort study suggest that for patients with multiple sclerosis, presenting with PIRA after a first demyelinating event was not uncommon and suggests an unfavorable long-term prognosis, especially if it occurs early in the disease course.
引用
- Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, et al. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis. JAMA Neurol. 2023. PMID: 36534392. doi:10.1001/jamaneurol.2022.4655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。